Immune changes beyond Th2 pathways during rapid multifood immunotherapy enabled with omalizumab.

ABSTRACT:

Background

Multifood oral immunotherapy (mOIT) with adjunctive anti-IgE (omalizumab, XOLAIR^® ) treatment affords safe, effective, and rapid desensitization to multiple foods, although the specific immune mechanisms mediating this desensitization remain to be fully elucidated.

Methods

Participants in our phase 2 mOIT trial (NCT02643862) received omalizumab from baseline to week 16 and mOIT from week 8 to week 36. We compared the immune profile of PBMCs and plasma taken at baseline, week 8, and week 36 using high-dimensional mass cytometry, component-resolved diagnostics, the indirect basophil activation test, and Luminex.

Results

We found (i) decreased frequency of IL-4⁺ peanut-reactive CD4⁺ T cells and a marked downregulation of GPR15

SUBMITTER: Manohar M 

PROVIDER: S-EPMC8609920 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature